North America Joint Pain Injections Market Size, Share & Industry Trends Analysis Report By Injection Type (Interleukin Inhibitors, Hyaluronic Acid Injections), By Distribution Channel, By Joint Type Channel, By Country and Growth Forecast, 2022 - 2028

North America Joint Pain Injections Market Size, Share & Industry Trends Analysis Report By Injection Type (Interleukin Inhibitors, Hyaluronic Acid Injections), By Distribution Channel, By Joint Type Channel, By Country and Growth Forecast, 2022 - 2028

The North America Joint Pain Injections Market would witness market growth of 7.0% CAGR during the forecast period (2022-2028).

The two most common varieties of arthritis are rheumatoid arthritis, an inflammatory condition that typically affects the hands and feet, and osteoarthritis, a degenerative joint disease. Growing older, becoming more obese, avoiding exercising, and diminishing bone mineral density are all risk factors for osteoarthritis. Hyaluronic acid and corticosteroid injections are frequently utilized to reduce swelling and discomfort in affected joint locations. Joint pain can be treated, and direct joint injections can reduce edema and inflammation. The majority of the time, pre-existing illnesses or abnormalities in the elderly are what causes joint discomfort. The primary sites of the spine most frequently affected by arthritis are the ankle, elbow, knee, hip, shoulder, and facet joints. The pain it causes in the joints, which then, in turn, causes inflammation, makes joint discomfort worse.

The therapy options that are currently accessible are insufficient because they mainly concentrate on symptom alleviation and pain management. There are now no medications that can treat, stop the progression of, or reverse diseases like osteoarthritis. There are significant unmet requirements in patients with joint pain since some people cannot relieve their pain with treatment options and continue to experience it. This opens the market for joint pain injections to more cutting-edge therapy alternatives.

According to the Centers for Disease Control and Prevention, there are currently 59 million persons with arthritis in the United States, an increase of over 4 million during 2013–2015. The population living with activity restrictions due to arthritis is expected to rise 46% by 2040, making it one of the top causes of disability in the nation (from 23.7 million during 2013–2015 to 34.6 million). Approximately 23% of US people are overweight, and 31% of those who are obese have arthritis that has been medically diagnosed.

A diagnosis of rheumatoid arthritis affects over 374,000 (1.2%) Canadians aged 16 and older, and 23,000 (0.8 per 1,000 people per year) people had a new diagnosis in 2016–2017. Rheumatoid arthritis diagnosis prevalence and incidence are higher in women than men and generally rise with age. The demand for joint pain injections is expected to increase significantly in North America due to the increased prevalence of arthritis in the region.

The US market dominated the North America Joint Pain Injections Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,817.2 Million by 2028. The Canada market is experiencing a CAGR of 9.5% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 8.5% during (2022 - 2028).

Based on Injection Type, the market is segmented into Interleukin Inhibitors, Hyaluronic Acid Injections, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Joint Type Channel, the market is segmented into Knee & Ankle, Shoulder & Elbow, Hip Joint, Facet Joints of the Spine, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioventus Inc., Pacira BioSciences, Inc., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc., Anika Therapeutics, Inc., Zimmer Biomet Holdings, Inc., Eli Lilly And Company, Ferring Holdings SA, and Sanofi S.A.

Scope of the Study

Market Segments covered in the Report:

By Injection Type

• Interleukin Inhibitors
• Hyaluronic Acid Injections
• Others

By Distribution Channel

• Drug Stores & Retail Pharmacies
• Hospital Pharmacies
• Others

By Joint Type

• Knee & Ankle
• Shoulder & Elbow
• Hip Joint
• Facet Joints of the Spine
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• Bioventus Inc.
• Pacira BioSciences, Inc.
• AbbVie, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Pfizer, Inc.
• Anika Therapeutics, Inc.
• Zimmer Biomet Holdings, Inc.
• Eli Lilly And Company
• Ferring Holdings SA
• Sanofi S.A.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free